Nicotinic acid: clinical considerations. - Test2 - elhamkhani - TriplyDB

Nicotinic acid: clinical considerations.

Nicotinic acid: clinical considerations.

http://www.wikidata.org/entity/Q38008035

about

Drug-induced hyperuricaemia and gout.Nicotinic acid supplementation in the context of alcoholic liver injury: friend or foe?

P2860

Q38920898-A6A2041F-88AB-4018-9339-ED57B09659B9 Q48251233-4EC9727B-DF35-45B4-B713-816A858A3E09

P2860

Nicotinic acid: clinical considerations.

http://www.wikidata.org/entity/Q38008035

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Nicotinic acid: clinical considerations.

@en

type

label

Nicotinic acid: clinical considerations.

@en

prefLabel

Nicotinic acid: clinical considerations.

@en

P1433

Q38008035-2BF32D82-0CE3-40AB-902E-1CF6F979C272

P1476

Q38008035-42471E52-0261-4C8C-B690-D14C693D9652

P2093

Q38008035-F502AA16-5E0D-48E9-9FB8-930812DFAD2E

P2860

Q38008035-05EE7D64-B457-4B66-97F3-925183C41FB2

Q38008035-071B9362-2DAC-4E98-BE11-83DE4C56F47D

Q38008035-07784AC2-7477-4BF2-B4F5-6FC0A7B17AC2

Q38008035-100703E4-1942-4F41-B53B-882666FB727C

Q38008035-13AB701B-B151-4349-A9DD-C0F0853D8738

Q38008035-1AD2F12A-52AF-4FF0-B482-BF7BA202CCB4

Q38008035-2153065E-F404-478A-85D6-4BA808E338A1

Q38008035-2887CDFD-170D-48E4-97AC-53C78CB64BB7

Q38008035-28D955AF-4A08-4F3A-A5DD-B5CD050716F7

Q38008035-29914B3E-334E-433A-B5EC-E58E97C2873B

P304

Q38008035-A4251F96-9E19-4306-8663-A39F5E44066E

P31

Q38008035-29052D91-1BB2-47D2-8E98-BCA24F2E81C5

P356

Q38008035-F98644F2-08DE-4DE7-83F8-9979C8053C0B

P407

Q38008035-C501BC44-F1E8-43F4-85EA-B89E81C940D3

P433

Q38008035-91B3ADA5-3020-4ED7-BDD8-E57F0AE5ED29

P478

Q38008035-ACEB228A-5870-4B8A-8904-9C361E5E6FD2

P50

Q38008035-3EE84F9F-E813-41E3-935B-111B1650D004

P577

Q38008035-3452E16A-ECA1-4F04-9C5C-BD495061D77A

P698

Q38008035-A6F76CEC-4432-4592-B10E-FE2A569E907C

P356

14740338.2012.682981

P1433

Expert Opinion on Drug Safety

P1476

Nicotinic acid: clinical considerations

@en

P2093

Anastazia Kei

http://www.w3.org/2001/XMLSchema#string

P2860

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

Regulation of hepatic ApoC3 expression by PGC-1β mediates hypolipidemic effect of nicotinic acid

Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice

Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin

Molecular identification of nicotinic acid receptor

Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial

Molecular identification of high and low affinity receptors for nicotinic acid

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

P304

551-564

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2012.682981

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22564238

http://www.w3.org/2001/XMLSchema#string